Positive data for tirzepatide


United States

Eli Lilly and Co has reported positive data for tirzepatide, an approved drug for obesity and type 2 diabetes, which is now being investigated for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease. Formerly known as non-alcoholic steatohepatitis, MASH results from an excess of fat in the liver which can lead to liver-related complications and death. The global prevalence of the disease is increasing.